LEIOMYOSARCOMA OF THE MAXILLARY SINUS : A CASE REPORT

상악동에 발생한 평활근 육종의 치험례

  • Choi, Se-Kyung (Department of Oral and Maxillofacial Surgery, College of Dentistry, Yonsei University) ;
  • Kim, Jae-Young (Department of Oral and Maxillofacial Surgery, College of Dentistry, Yonsei University) ;
  • Kim, So-Mi (Department of Oral and Maxillofacial Surgery, College of Dentistry, Yonsei University) ;
  • Kim, Hyun-Woo (Department of Oral and Maxillofacial Surgery, College of Dentistry, Yonsei University) ;
  • Nam, Jung-Woo (Department of Oral and Maxillofacial Surgery, College of Dentistry, Yonsei University) ;
  • Nam, Woong (Department of Oral and Maxillofacial Surgery, College of Dentistry, Yonsei University) ;
  • Cha, In-Ho (Department of Oral and Maxillofacial Surgery, College of Dentistry, Yonsei University) ;
  • Kim, Hyung-Jun (Department of Oral and Maxillofacial Surgery, College of Dentistry, Yonsei University)
  • 최세경 (연세대학교 치과대학병원 구강악안면외과) ;
  • 김재영 (연세대학교 치과대학병원 구강악안면외과) ;
  • 김소미 (연세대학교 치과대학병원 구강악안면외과) ;
  • 김현우 (연세대학교 치과대학병원 구강악안면외과) ;
  • 남정우 (연세대학교 치과대학병원 구강악안면외과) ;
  • 남웅 (연세대학교 치과대학병원 구강악안면외과) ;
  • 차인호 (연세대학교 치과대학병원 구강악안면외과) ;
  • 김형준 (연세대학교 치과대학병원 구강악안면외과)
  • Published : 2009.12.31

Abstract

Leiomyosarcoma(LMS) is a malignant neoplasm of smooth muscle origin, which accounts for 7 % of all soft tissue sarcomas. The most common sites are the gastrointestinal tract and female genital tract. In contrast, primary LMS of the oral and maxillofacial area is rare due to the paucity of smooth muscle in this region. Especially, LMS of the paranasal sinuses is very rare and has an aggressive clinical behavior. Only 28 cases have been described in the english literature, and of these, only 3 patients treated with surgery had a disease-free survival. A 46-year-old woman came to our department for the evaluation of pain on right midface. After a diagnostic work-up, the lesion was diagnosed as LMS of the right maxillary sinus. The radical surgery was done and chemotherapy combined radiotherapy was followed from post operation 1 month. The patient was disease free at post-operation 1 year. We will report this case with literature review.

Keywords

References

  1. Yadav R, Bharathan S: Leiomyosarcoma of the buccal mucosa: a case report with immunohistochemistry findings. J Oral Sci 2008;50:215-218 https://doi.org/10.2334/josnusd.50.215
  2. Schenberg ME, Slootweg PJ, Koole R: Leiomyosarcomas of the oral cavity. Report of four cases and review of the literature. J Craniomaxillofac Surg 1993;21:342-347 https://doi.org/10.1016/S1010-5182(05)80495-0
  3. Ethunandan M, Stokes C, Higgins B, Spedding A, Way C, Brennan P: Primary oral leiomyosarcoma: a clinico-pathologic study and analysis of prognostic factors. Int J Oral Maxillofac Surg 2007;36:409-416 https://doi.org/10.1016/j.ijom.2006.12.015
  4. Fusconi M, Magliulo G, Della Rocca C, Marcotullio D, Suriano M, de Vincentiis M: Leiomyosarcoma of the sinonasal tract: a case report and literature review. Am J Otolaryngol 2002;23:108-111 https://doi.org/10.1053/ajot.2002.30628
  5. Vilos GA, Rapidis AD, Lagogiannis GD, Apostolidis C: Leiomyosarcomas of the oral tissues: clinicopathologic analysis of 50 cases. J Oral Maxillofac Surg 2005;63:1461-1477 https://doi.org/10.1016/j.joms.2005.06.018
  6. Farman AG, Kay S: Oral leiomyosarcoma. Report of a case and review of the literature pertaining to smooth-muscle tumors of the oral cavity. Oral Surg Oral Med Oral Pathol 1977;43:402-409 https://doi.org/10.1016/0030-4220(77)90327-9
  7. Prasad KC, Alva TB, Khadilkar U, Madhu D: Leiomyosarcoma of the maxillary sinuses: report of two cases. Ear Nose Throat J 2004;83:122, 124, 126-127
  8. Izumi K, Maeda T, Cheng J, Saku T: Primary leiomyosarcoma of the maxilla with regional lymph node metastasis. Report of a case and review of the literature. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1995;80:310-319 https://doi.org/10.1016/S1079-2104(05)80389-0
  9. Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, Morrison W, et al.: Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003;349:2091-2098 https://doi.org/10.1056/NEJMoa031317
  10. Issels RD, Schlemmer M: Current trials and new aspects in soft tissue sarcoma of adults. Cancer Chemother Pharmacol 2002;49 Suppl 1:S4-8 https://doi.org/10.1007/s00280-002-0445-3
  11. Barnes L. Pathology and genetics of head and neck tumours. Lyon, IARC Press,2005;39
  12. Neville BW. Oral and maxillofacial pathology 3rd ed. ed. Edinburgh, Saunders,2009;559
  13. Pinheiro Jde J, Alves Sde M, Jr., Okuda E, Jorge WA, Jaeger RG, de Araujo NS: Primary leiomyosarcoma of the mandible. A case report. Med Oral Patol Oral Cir Bucal 2007;12:E56-59
  14. Montgomery E, Goldblum JR, Fisher C: Leiomyosarcoma of the head and neck: a clinicopathological study. Histopathology 2002;40:518-525 https://doi.org/10.1046/j.1365-2559.2002.01412.x
  15. Miettinen M, Lehto VP, Ekblom P, Tasanen A, Virtanen I: Leiomyosarcoma of the mandible: diagnosis as aided by immunohistochemical demonstration of desmin and laminin. J Oral Pathol 1984;13:373-381 https://doi.org/10.1111/j.1600-0714.1984.tb01436.x
  16. Santoro A, Tursz T, Mouridsen H, Verweij J, Steward W, Somers R, et al.: Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 1995;13:1537-1545 https://doi.org/10.1200/JCO.1995.13.7.1537
  17. van Oosterom AT, Mouridsen HT, Nielsen OS, Dombernowsky P, Krzemieniecki K, Judson I, et al.: Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and secondline chemotherapy in advanced soft tissue sarcoma patients. Eur J Cancer 2002;38:2397-2406 https://doi.org/10.1016/S0959-8049(02)00491-4
  18. Maki RG, Wathen JK, Patel SR, Priebat DA, Okuno SH, Samuels B, et al.: Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]. J Clin Oncol 2007;25:2755-2763 https://doi.org/10.1200/JCO.2006.10.4117
  19. Worden FP, Taylor JM, Biermann JS, Sondak VK, Leu KM, Chugh R, et al.: Randomized phase II evaluation of 6 g/m2 of ifosfamide plus doxorubicin and granulocyte colony-stimulating factor (G-CSF) compared with 12 g/m2 of ifosfamide plus doxorubicin and G-CSF in the treatment of poor-prognosis soft tissue sarcoma. J Clin Oncol 2005;23:105-112 https://doi.org/10.1200/JCO.2005.05.108